A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease

<div>Forest plots of the standardized mean difference in Unified Parkinson’s Disease Rating Scale II (UPDRS II (a)) and III (UPDRS III (b)) following the administration of rasagiline at 1 mg/day. Rasagiline improved both UPDRS II and UPDRS scores. Significant heterogeneity was seen in the included studies.</div>

Parkinson’s Disease

fig3

Figure 3

Figure 3: A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease 

Figure 3 | A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease 